会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS
    • 取代的咪唑烷作为CANNABINOID受体调节剂
    • WO03007887A3
    • 2003-04-17
    • PCT/US0223230
    • 2002-07-16
    • MERCK & CO INCFINKE PAUL EMILLS SANDER GPLUMMER CHRISTOPHER WSHAH SHRENIK KTRUONG QUANG T
    • FINKE PAUL EMILLS SANDER GPLUMMER CHRISTOPHER WSHAH SHRENIK KTRUONG QUANG T
    • A61P21/04A61P25/08A61P25/16A61P25/18A61P25/30C07D233/90C07D405/12C08K5/34A61K31/415
    • C07D405/12C07D233/90
    • The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1)receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.
    • 使用本发明的化合物作为大麻素-1(CB1)受体的拮抗剂和/或反向激动剂,特别是用于治疗,预防和抑制由大麻素-1(CB1)受体介导的疾病。 本发明涉及这些新化合物选择性拮抗大麻素-1(CB1)受体的用途。 因此,本发明的化合物可用作治疗精神病,记忆缺陷,认知障碍,偏头痛,神经病,包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的精神药物。 血管意外和头部创伤,焦虑障碍,压力,癫痫,帕金森病和精神分裂症。 这些化合物也可用于治疗药物滥用障碍,特别是鸦片剂,酒精和尼古丁。 所述化合物还可用于治疗与过量食物摄入和与其相关的并发症相关的肥胖或进食障碍。 还要求新的结构式(I)化合物。